[Congress] Bio Spring Europe, March 22-25, 2021

[Congress] Bio Spring Europe, March 22-25,2021

Oncodesign BU Services  and Oncodesign BU Biotech will be present at BIO SPRING Europe 2021. Find your innovative & scientific solution provider or partner!

  • •Oncodesign BU Service is an innovation-based solutions and expertise provider in Drug Discovery in Oncology, Immuno-oncology, Infectious Diseases (Covid-19) and Inflammatory Diseases.
  • •Oncodesign BU Biotech is a clinical-stage drug discovery Business Unit that capitalizes on its next-generation kinase inhibitor technology called Nanocyclix® consisting of highly potent and selective small macrocycles to tackle novel and untractable kinases of interest.

Oncodesign Service - DRIVE-IDDS™  premium and integrated offering from Hit Finding to IND filing

This offering encloses multiple innovative hit-finding/screening capabilities, medicinal chemistry, computational chemistry, in vitro biology, ADME / DMPK, in vivo pharmacology, pharmaco-imaging/theranostic and safety assessment all applied in one-stop shop to drug discovery programs in oncology, immuno-oncology, auto-immune/ inflammatory diseases. 

DRIVE-SM

DRIVE-SM is our integrated discovery engine for small molecule discovery and development - from Hit Finding to IND filing - in oncology and inflammatory diseases. Access to our multiple innovative hit-finding solutions, computational and medicinal chemistry, in vitro biology, ADME / DMPK, in vivo pharmacology and pharmaco-imaging expertise and capabilities all in one-stop shop.

This email address is being protected from spambots. You need JavaScript enabled to view it.

DRIVE STRT

DRIVE-STRT is our new platform to enable the generation of novel systemic targeted radiotherapeutics in clinical oncology.

Oncodesign and its strategic partners are applying their expertise in the rationalization, in the design, and in the optimization of targeted radiopharmaceutical agents effective against specific cancers, with demonstration of preclinical proof of concept and safety margins, from the preclinical to the early clinical stages of your project. 

This email address is being protected from spambots. You need JavaScript enabled to view it.

Oncodesign Biotech - Value creation through innovative technology Nanocyclix®

Using its Nanocyclix® technology, Oncodesign identifies small macrocyclic molecules capable of inhibiting both unexplored and intractable kinases in a powerful and targeted manner. The approach is "Probe based" rather than "Target based", meaning that potent and selective kinase inhibitor "Probes" are directly generated using the macrocyclic chemistry platform. These probes allow to identify accessible kinases using  a broad profiling approach and are used for early cellular Proof of Concept of the kinase(s) of interest in specific disease indications.

A large variety of kinase inhibitors are thus explored continuously, and the most promising inhibitor/targeted kinase combinations are selected for more in depth investigations. 

Oncodesign has built a project portfolio with strong potential to treat diseases with high unmet medical needs. This portfolio contains both molecules already at an advanced stage of clinical development (a PET tracer for a specific type of lung cancer) and molecules at an earlier stage of development.

Recent successes include strong advancement on LRRK2 inhibitors for Parkinson disease - a notoriously difficult kinase (in partnership with Servier), and the selection of a first in class candidate drug against the novel kinase RIPK2, a promising target in immuno-inflammation and auto-immune diseases. The latter is subject to ongoing partnering discussions and is advancing on its route towards IND in 2021

Set up your appointment with Jan Hoflack

[Congress] Microbiota & Health Day - 26 January, 2021

[Congress] Microbiota & Health Day - 26 January, 2021

Tailor-made strategies to your needs for the investigation of the efficacy of your bacteria-based treatments and/or the effect of your therapies on microbiota.

Join Dr. Sylvie Maubant and Emilie Soulier to discover how Oncodesign assess the interplay between tumor or inflammatory disease of interest (e.g. colitis), microbiota and therapies.

Our comprehensive platform dedicated to microorganisms helps you to investigate in vitro and/or in vivo the bacteria as immuno-modulating vectors or agents.

Our teams have developed models for pathologies related to microbiota disorders and therefore can customize studies for programs from preclinical to early clinical phases.

We guide you on all projects on bacteria-based therapies or any treatment acting on microbiota across different therapeutic areas i.e. oncology and inflammatory diseases.

I contact Sylvie & Emilie!

I know to know more!

[Congress] J.P. Morgan Healthcare Conference & Biotech Showcase, 11-15 January, 2021

[Congress] Biotech Showcase, January 11-15, 2021

Seeking for partners on drug discovery programs based on our Nanocyclix platform as next-generation kinase inhibitors.

Using its Nanocyclix® technology, Oncodesign identifies small macrocyclic molecules capable of inhibiting both known and unexplored kinases in a powerful and targeted manner

A large variety of kinase inhibitors are thus explored continuously, and the most promising inhibitor/targeted kinase combinations are selected for more in depth investigations. 

Oncodesign has built a project portfolio with promising potential to treat diseases with very substantial unmet medical needs. This portfolio contains both molecules already at an advanced stage of clinical development and molecules at an earlier stage of development.

Connect with Dr. Jan Hoflack - Chief Scientific Officer and Executive Director, Head of Biotech Business Unit – to discuss Oncodesign’s partnering and licensing opportunities:

  • A RIPK2 inhibitor at pre-IND stage with potential in multiple auto-immune and inflammatory indications is presented for partnering/out-licensing
  • Lead stage programs available for partnership on attractive kinases: MNK1/2, ALK1, ALK2, CK1, Pikfyve, CDK7, PI3K, RET, ...
  • Nanocyclix based partnerships on your kinase targets

This email address is being protected from spambots. You need JavaScript enabled to view it.

Are you looking for an innovation-based solutions and expertise provider in Drug Discovery?

Oncodesign is offering DRIVE-IDDS™ an Integrated Drug Discovery Services for the discovery of new chemical entities from hits finding to clinical candidate as a one-stop-shop.

Fabrice Viviani - General Manager and Senior Executive Vice-President, Head of Oncodesign Service Business Unit - will attend Biotech Showcase and JP Morgan Healthcare Conference. He will be pleased to introduce our technology platforms supporting translational research from the early stages of the drug discovery process up to clinical candidate generation - a real driver of innovation, acceleration & success for your NCE programs.

This email address is being protected from spambots. You need JavaScript enabled to view it.

[Congress] [FR] E-Senotech, 1st Congress on Breast Health in the Digital Age

[Congress] [FR] E-Senotech, 1st Congress on Breast Health in the Digital Age

Connected objects, artificial intelligence and big data are an integral part of our daily life.

Discover at E-SENOTECH how these innovations help to identify the problems of resistance to cancer treatments.

Breast cancer is still a public health issue in France and around the world.

Technological innovations are enabling considerable progress in the prevention & treatment of breast cancers, which is why the ICANS | Institute of Cancerology is offering you the SENOTECH congress.

Scientists, industrials, institutions, health professionals & patient representatives will be present to address the various topics of the day & answer your questions.

Come & listen the Big Data session on December 11st, 2020 at 11am co-animated by Sébastien Vachenc, Head of Data Science Labs.

[Talk][FR] Large-scale genomics to orient breast cancer treatment

I register for free